Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain.

Original languageEnglish
Pages (from-to)3331-3333
Number of pages3
JournalClinical Cancer Research
Issue number13
StatePublished - Jul 1 2013


Dive into the research topics of 'A neu view of invasive lobular breast cancer'. Together they form a unique fingerprint.

Cite this